行情

CELG-RT

CELG-RT

Celgene
NYSE

实时行情|Nasdaq Last Sale

0.2650
+0.0250
+10.42%
交易中 10:46 06/17 EDT
开盘
0.2500
昨收
0.2400
最高
0.2650
最低
0.2500
成交量
6,932
成交额
--
52周最高
0.4900
52周最低
0.1903
市值
1.89亿
市盈率(TTM)
0.0331
分时
5日
1月
3月
1年
5年
重温-《路透简报》--中国重要财经新闻一周回顾
reuters.com · 05/30 23:30
重溫-《路透簡報》--中國重要財經新聞一周回顧
reuters.com · 05/30 23:30
《路透簡報》--中國重要財經新聞一周回顧
reuters.com · 05/28 03:20
《路透简报》--中国重要财经新闻一周回顾
reuters.com · 05/28 03:20
下修第二季伺服器出货季成长率预测,中国科企海外扩展欠积极--TrendForce
reuters.com · 05/27 07:16
下修第二季伺服器出貨季成長率預測,中國科企海外擴展欠積極--TrendForce
reuters.com · 05/27 07:16
中國邁瑞醫療擬5.45億歐元收購Hytest及其子公司股權,發力體外診斷產品
reuters.com · 05/17 00:58
中国迈瑞医疗拟5.45亿欧元收购Hytest及其子公司股权,发力体外诊断产品
reuters.com · 05/17 00:58
更多
财务预测
暂无数据
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CELG-RT最新的财务预测,通过CELG-RT每股收益,每股净资产,每股现金流等数据分析Celgene近期的经营情况,然后做出明智的投资选择。
暂无数据
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.27%
制药与医学研究
-0.36%
高管信息
Chairman/Chief Executive Officer/Director
Mark Alles
Executive Vice President
Peter Kellogg
Corporate Executive
Terrie Curran
Corporate Executive
Rupert Vessey
Corporate Executive
Michael Pehl
Executive Vice President/General Counsel
Jonathan Biller
Executive Vice President/General Counsel/Secretary
Gerald Masoudi
Chief Financial Officer/Executive Vice President
David Elkins
Lead Director
Michael Casey
Director
Hans Bishop
Director
Julia Haller
Independent Director
Richard Barker
Director
Patricia Hall
Independent Director
Michael Bonney
公告日期
每股分红
除权日期
--
每股分红:USD 6.932592
2013/10/08
CELG-RT 简况
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

微牛提供Celgene Corporation(NYSE-CELG RT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CELG RT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CELG-RT股票基本功能。